A systematic review of the safety of topical therapies for atopic dermatitis

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 203-221

  Callen, J ^a   Chamlin, S ^b   Eichenfield, L F ^c   Ellis, C ^d   Girardi, M ^e   Goldfarb, M ^d   Hanifin, J ^f   Lee, P ^c   Margolis, D ^g   Paller, A S ^b   Piacquadio, D ^c   Peterson, W ^h   Kaulback, K ⁱ   Fennerty, M ^f   Wintroub, B U ^j  

^a University of Louisville School of Medicine   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Safety; Steroids

Indexed keywords

ALCLOMETASONE; CALCINEURIN INHIBITOR; CLOBETASOL; COAL TAR; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYANOCOBALAMIN; CYCLOSPORIN; DESONIDE; DOXEPIN; FLUOCINOLONE; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; MOMETASONE FUROATE; NEOMYCIN; PHOSPHODIESTERASE INHIBITOR; PIMECROLIMUS; PREDNICARBATE; STEROID; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ACNE; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ATOPIC DERMATITIS; BENIGN SKIN TUMOR; BURN; CHICKENPOX; CLINICAL TRIAL; COCHRANE LIBRARY; DERMATITIS; DRUG ABSORPTION; DRUG EFFECT; DRUG ERUPTION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRY SKIN; ECZEMA; EMBASE; ERYTHEMA; EVIDENCE BASED MEDICINE; EXFOLIATIVE DERMATITIS; FOLLICULITIS; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IRRITANT DERMATITIS; LOW DRUG DOSE; MACULOPAPULAR RASH; MEDLINE; MOLLUSCUM CONTAGIOSUM; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; SARCOMA; SEDATION; SIDE EFFECT; SKIN ALLERGY; SKIN ATROPHY; SKIN CARCINOMA; SKIN DISEASE; SKIN INFECTION; SKIN LYMPHOMA; SKIN TINGLING; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; STRIA; SUBCAPSULAR CATARACT; SUNBURN; SUPERINFECTION; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VERRUCA VULGARIS;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; COST OF ILLNESS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 33846242915     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07538.x     Document Type: Review

References (234)

1. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003; 361:151-60.
2. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112:S118-27.
3. Williams HC. Atopic eczema - why we should look at the environment. BMJ 1995; 311:1241-2.
4. Williams HC. Atopic dermatitis. N Engl J Med 2005; 352:2314-24.
5. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic dermatitis. Health Technol Assess 2000; 4:1-191.
6. Ashcroft DM, Dimmick P, Garside R et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330:516-22.
7. Boner AL, Richelli C, De Stefano G et al. Adrenocortical function during prolonged treatment with clobetasone butyrate in children with chronic atopic dermatitis and elevated IgE levels. Int J Clin Pharmacol Res 1985; 5:127-31.
8. Allen BR, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88:969-73.
9. Food and Drug Administration. Pediatric Advisory Committee. Briefing Information, 15 February 2005. Available at: http://www.fda.-gov/ohrms/ dockets/ac/05/briefing/2005-4089b2.htm (accessed on 6 August 2006).
10. Bieber T, Cork M, Ellis C et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211:77-8.
11. Ellison JA, Patel L, Ray DW et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000; 105:794-9.
12. Jones SK, MacKie RM, Hole DJ, Gillis CR. Further evidence of the safety of tar in the management of psoriasis. Br J Dermatol 1985; 113:97-101.
13. Pittelkow M, Perry H, Muller S et al. Skin cancer in patients with psoriasis treated with coal tar. Arch Dermatol 1981; 117:465-8.
14. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998; 90:1278-83.
15. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73:2759-64.
16. Maughan WZ, Muller SA, Perry HO et al. Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. A 25-year follow-up study. J Am Acad Dermatol 1980; 3:612-15.
17. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczemous dermatitis. Doxepin Study Group. Arch Dermatol 1995; 131:1403-8.
18. Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994; 31:613-16.
19. Fisher AA. The antihistamines. J Am Acad Dermatol 1980; 3:303-6.
20. Angelini G. Topical drugs. In: Textbook of Contact Dermatitis (Rycroft RJG, Menné T, Frosch PJ, eds), 2nd edn. Berlin: Springer-Verlag, 1995; 490.
21. Shelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996; 34:143-4.
22. Bioglan Pharma Package Insert - Zonalon (Doxepin Hydrochloride) Cream, 5%. Malvern, PA: 2002 (updated).
23. Jappe U, Schnuch A, Uter W. Sensitization to antimicrobials in atopic eczema. Br J Dermatol 2003; 149:87-93.
24. From Food and Drug Administration via Freedom of Information Act summary basis of approval for various topical antibiotics including erythromycin, clinidamycin, and topical antiseptics with agents such as chlohexidine, chloroxylenol etc. www.fda.gov.
25. Akers PA. Risks of unoccluded topical steroids in clinical trials. Arch Dermatol 1980; 116:786-8.
26. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomized, double-blind, parallel group study. BMJ 2003; 326:1-6.
27. Friedlander F, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002; 46:387-93.
28. Freeman S, Howard A, Foley P et al. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen®) vs. vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. Australas J Dermatol 2002; 43:186-9.
29. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147:528-37.
30. Korting G. 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 1992; 42:159-61.
31. From Food and Drug Administration via Freedom of Information Act summary basis of approval for various topical steroids including fluticasone propionate, clobetasol propionate etc. www.fda.gov.
32. Morren N, Dooms-Goossens D. Corticosteroid allergy in children: a potential complication of atopic eczema. Eur J Dermatol 1994; 4:106-9.
33. Wilkinson TA. Hydrocortisone sensitivity: clinical features of fifty-nine cases. J Am Acad Dermatol 1992; 27:683-7.
34. Alani SD, Alani MD. Allergic contact dermatitis and conjunctivitis to corticosteroids. Contact Dermatitis 1976; 2:301-4.
35. Foti C, Bonifazi E, Casulli C et al. Contact allergy to topical corticosteroids in children with atopic dermatitis. Contact Dermatitis 2005; 52:162-3.
36. Ingber A. What's new in contact dermatitis: allergy to topical steroids in Israeli patients with contact dermatitis. Isr Med Assoc J 2002; 4 (Suppl. 11):867.
37. Branco BA. Cutaneous corticosteroid therapy and cataract in man. J Toxicol Cutaneous Ocul Toxicol 2002; 21:161-8.
38. From Food and Drug Administration via Freedom of Information Act summary basis of approval for various topical steroids including fluticasone propionate - topical dosage form, mometasone furoate - inhalation dosage form only. www.fda.gov.
39. Reitamo S, Wollenberg A, Schopf E et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136:999-1006.
40. Bekersky I, Fitzsimmons W, Tanase A et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44 (Suppl. 1):S17-27.
41. Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (Suppl. 1):S58-64.
42. Paller A, Eichenfield LF, Leung DY et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (Suppl. 1):S47-57.
43. Soter NA, Fleischer AB Jr, Webster GF et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II. Safety. J Am Acad Dermatol 2001; 44 (Suppl. 1):S39-46.
44. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46:495-504.
45. Wahn U, Bos JD, Goodfield M et al. Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110:e2.
46. Ho VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142:155-62.
47. Furue M, Terao H, Moroi Y et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol 2004; 31:277-83.
48. Kempers S, Boguniewicz M, Carter E et al. Investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51:515-25.
49. Luger TA, Lahfa M, Folster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15:169-78.
50. Meurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208:365-72.
51. Nakahara T, Koga T, Fukagawa S et al. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/ emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004; 31:524-8.
52. Papp K, Staab D, Harper J et al. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int J Dermatol 2004; 43:978-83.
53. Wellington K, Noble S. Pimecrolimus: a review of its use in atopic dermatitis. Am J Clin Dermatol 2004; 5:479-95.
54. Hanifin JM, Paller AS, Eichenfield L et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53 (2 Suppl. 2):S186-94.
55. Wolff K, Fleming C, Hanifin J et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005; 152:1296-303.
56. Fleischer AB, Ling M, Eichenfield L et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47:562-70.
57. Reitamo S, Ortonne JP, Sand C et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152:1282-9.
58. Food and Drug Administration. Alerts for Healthcare Professionals, March 2005. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/ elidelHCP.htm and http://www.fda.gov/cder/drug/InfoSheets/HCP/ProtopicHCP.htm (accessed on 6 August 2006).
59. Veenhuis RT, van Horssen J, Bos RP et al. Highly increased urinary 1-hydroxypyrene excretion rate in patients with atopic dermatitis treated with topical coal tar. Arch Dermatol Res 2002; 294:168-71.
60. Turpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, Salo OP. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol 1988; 5:276-9.
61. Hehir M, Du Vivier A, Eilon L. Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol 1983; 8:143-51.
62. McGowan R, Tucker P, Joseph D et al. Short-term growth and bone turnover in children undergoing occlusive steroid ('wet-wrap') dressings for treatment of atopic eczema. J Dermatolog Treat 2003; 14:149-52.
63. Kristmundsdottir F, David TJ. Growth impairment in children with atopic eczema. J R Soc Med 1987; 80:9-12.
64. Wolthers OD, Heuck C, Ternowitz T et al. Insulin-like growth factor axis, bone and collagen turnover in children with atopic dermatitis treated with topical glucocorticosteroids. Dermatology 1996; 192:337-42.
65. Aalto-Korte K, Turpeinen M. Bone mineral density in patients with atopic dermatitis. Br J Dermatol 1997; 136:172-5.
66. Patel L, Clayton PE, Jenney ME et al. Adult height in patients with childhood onset atopic dermatitis. Arch Dis Child 1997; 76:505-8.
67. Patel L, Clayton PE, Addison GM et al. Linear growth in prepubertal children with atopic dermatitis. Arch Dis Child 1998; 79:169-72.
68. Hoetzenecker W, Meingassner JG, Ecker R et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122:673-84.
69. Lesko MJ, Lever RS, MacKie RM, Parrott DM. The effect of topical steroid application on natural killer cell activity. Clin Exp Allergy 1989; 19:633-6.
70. Harper J, Smith C, Rubins A et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124:695-9.
71. Tandon V. Systemic Exposure of Topical Tacrolimus. Office of Clinical Pharmacology and Biopharmaceutics. Available at: http://www.fda.gov/ohrms/ dockets/ac/00/slides/3659s1_05_Tandon/ (accessed on 6 August 2006).
72. Alaiti S, Kang S, Fiedler V et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38:69-76.
73. Stiehm ER, Roberts RL, Kaplan MS et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005; 53 (2 Suppl. 2):S206-13.
74. Thaci D, Steinmeyer K, Ebelin ME et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 2003; 207:37-42.
75. Ling M, Gottlieb A, Pariser D et al. Randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. J Dermatolog Treat 2005; 16:142-8.
76. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269:29-35.
77. Papp K, Breuer K, Meurer M et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005; 52:247-53.
78. Food and Drug Administration. Postmarketing Safety Review - PID D030565. Drugs: Topical Corticosteroids. Rockville, MD: FDA Memorandum, 2003. www.fda.gov.
79. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48.
80. Food and Drug Administration. February 15th Meeting, Labeling Information, and NDAs. Available at: http://www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4089b2.htm (accessed on 6 August 2006).
81. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149:960-7.
82. Jiang H, Yamamoto S, Nishikawa K, Kato R. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis 1993; 14:67-71.
83. Yamamoto S, Jiang H, Kato R. Inhibition of anthralin-caused skin tumor promotion and interleukin-1 alpha production by potent immunosuppressant FK506. Cancer Lett 1994; 83:185-9.
84. Yokota K, Gill TJ, Shinozuka H. Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis. Cancer Res 1989; 49:4586-90.
85. Lubbe J, Sorg O. Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. Br J Dermatol 2004; 151:1275-6.
86. Daniel D, Meyer-Morse N, Bergsland EK et al. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 2003; 197:1017-28.
87. Siegel CT, Schreiber K, Meredith SC et al. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 2000; 191:1945-56.
88. Girardi M, Glusac E, Filler RB et al. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003; 198:747-55.
89. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001; 411:390-5.
90. Kim HK, Jin SY, Lee NS et al. Posttransplant primary cutaneous Ki-1 (CD30)+/CD56+ anaplastic large cell lymphoma. Arch Pathol Lab Med 2004; 128:e96-9.
91. Thomsen K, Wantzin GL. Extracutaneous spreading with fatal outcome of mycosis fungoides in a patient treated with cyclosporin A: a word of caution. Dermatologica 1987; 174:236-8.
92. Catterall MD, Addis BJ, Smith JL, Coode PE. Sézary syndrome: transformation to a high grade T-cell lymphoma after treatment with cyclosporin A. Clin Exp Dermatol 1983; 8:159-69.
93. Mahe E, Descamps V, Grossin M et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003; 149:170-3.
94. Corazza M, Zampino MR, Montanari A et al. Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003; 206:330-3.
95. Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol 2002; 47 (Suppl. 2):S165-7.
96. Zackheim HS, Koo J, LeBoit PE et al. Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine. J Am Acad Dermatol 2002; 47:155-7.
97. Pielop JA, Jones D, Duvic M. Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol 2001; 40:505-11.
98. Thomas M, Chandi SM, George S et al. Sézary syndrome - unmasked by cyclosporine. Int J Dermatol 1998; 37:957-8.
99. Cooper DL, Braverman IM, Sarris AH et al. Cyclosporine treatment of refractory T-cell lymphomas. Cancer 1993; 71:2335-41.
100. McMullan DM, Radovaneevic B, Jackow CM et al. Cutaneous T-cell lymphoma in a cardiac transplant recipient. Tex Heart Inst J 2001; 28:203-7.
101. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
102. Muller AM, Ihorst G, Mertelsmann R et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84:1-12.
103. Cartwright RA, McKinney PA, O'Brien C et al. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leuk Res 1988; 12:81-8.
104. Bernard SM, Cartwright RA, Bird CC et al. Aetiologic factors in lymphoid malignancies: a case-control epidemiological study. Leuk Res 1984; 8:681-9.
105. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992; 52:S5510-15.
106. Grulich AE, Vajdic CM, Kaldor JM et al. Birth order, atopy, and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005; 97:587-94.
107. Soderberg KC, Hagmar L, Schwartzbaum J, Feychting M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 2004; 4:51.
108. Doody MM, Linet MS, Glass AG et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992; 3:449-56.
109. Hagstromer L, Ye W, Nyren O et al. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005; 141:1123-7.
110. Turner MC, Chen Y, Krewski D et al. Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005; 162:212-21.
111. Talbot-Smith A, Fritschi L, Divitini ML et al. Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003; 157:606-12.
112. Castaing M, Youngson J, Zaridze D et al. Is the risk of lung cancer reduced among eczema patients? Am J Epidemiol 2005; 162:542-7.
113. Wen W, Shu XO, Linet MS et al. Allergic disorders and the risk of childhood acute lymphoblastic leukemia (United States) Cancer Causes Control 2000; 11:303-7.
114. Agnew KL, Ruchlemer R, Catovsky D et al. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150:1129-35.
115. Rosenbaum PF, Buck GM, Brecher ML. Allergy and infectious disease histories and the risk of childhood acute lymphoblastic leukaemia. Paediatr Perinat Epidemiol 2005; 19:152-64.
116. Schuz J, Morgan G, Bohler E et al. Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer 2003; 105:255-60.
117. Spector L, Groves F, DeStefano F et al. Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia. Eur J Cancer 2004; 40:579-84.
118. Holly EA, Eberle CA, Bracci PM. Prior history of allergies and pancreatic cancer in the San Francisco Bay area. Am J Epidemiol 2003; 158:432-41.
119. Negri E, Bosetti C, La VC et al. Allergy and other selected diseases and risk of colorectal cancer. Eur J Cancer 1999; 35:1838-41.
120. Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80:1830-7.
121. Ye W, Chow WH, Lagergren J et al. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients hospitalized for asthma. Br J Cancer 2001; 85:1317-21.
122. Brenner AV, Linet MS, Fine HA et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002; 99:252-9.
123. Schwartzbaum J, Jonsson F, Ahlbom A et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 2003; 106:423-8.
124. Milan T, Verkasalo PK, Kaprio J et al. Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br J Dermatol 2003; 149:115-23.
125. Ming ME, Levy RM, Hoffstad OJ et al. Validity of patient self-reported history of skin cancer. Arch Dermatol 2004; 140:730-5.
126. Montgomery SM, Ehlin AG, Sparen P et al. Childhood indicators of susceptibility to subsequent cervical cancer. Br J Cancer 2002; 87:989-93.
127. Becker N, Deeg E, Nieters A. Population-based study of lymphoma in Germany: rationale, study design and first results. Leuk Res 2004; 28:713-24.
128. Becker N, Deeg E, Rudiger T, Nieters A. Medical history and risk for lymphoma: results of a population-based case-control study in Germany. Eur J Cancer 2005; 41:133-42.
129. Boffett P, Ye W, Boman G, Nyren O. Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden. Eur Respir J 2002; 19:127-33.
130. Bosetti C, Talamini R, Franceschi S et al. Allergy and the risk of selected digestive and laryngeal neoplasms. Eur J Cancer Prev 2004; 13:173-6.
131. Briggs NC, Levine RS, Brann EA. Allergies and risk of non-Hodgkin's lymphoma by subtype. Cancer Epidemiol Biomarkers Prev 2002; 11:401-7.
132. Broberg A, Augustsson A. Atopic dermatitis and melanocytic naevi. Br J Dermatol 2000; 142:306-9.
133. Hedderson MM, Malone KE, Daling JR, White E. Allergy and risk of breast cancer among young women (United States). Cancer Causes Control 2003; 14:619-26.
134. Jourdan-Da Silva N, Perel Y, Mechinaud F et al. Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemia. Br J Cancer 2004; 90:139-45.
135. Kogevinas M, Zock JP, Alvaro T et al. Occupational exposure to immunologically active agents and risk for lymphoma. Cancer Epidemiol Biomarkers Prev 2004; 13:1814-18.
136. Lee WJ, Cantor KP, Berzofsky JA et al. Non-Hodgkin's lymphoma among asthmatics exposed to pesticides. Int J Cancer 2004; 111:298-302.
137. Mehrany K, el-Azhary RA, Bouwhuis SA, Pittelkow MR. Cutaneous T-cell lymphoma and atopy: is there an association? Br J Dermatol 2003; 149:1013-17.
138. Menegaux F, Olshan AF, Neglia JP et al. Day care, childhood infections, and risk of neuroblastoma. Am J Epidemiol 2004; 159:843-51.
139. Pompei R, Lampis G, Ingianni A et al. Allergy and tumour outcome after primary cancer therapy. Int Arch Allergy Immunol 2004; 133:174-8.
140. Rohan P, Komenda S. Contribution to the coincidence of malignant tumours and some allergic manifestations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002; 146:95-8.
141. Santillan AA, Camargo CA Jr, Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control 2003; 14:327-34.
142. Schabath MB, Delclos GL, Martynowicz MM et al. Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol 2005; 161:412-22.
143. Synnerstad I, Nilsson L, Fredrikson M, Rosdahl I. Fewer melanocytic nevi found in children with active atopic dermatitis than in children without dermatitis. Arch Dermatol 2004; 140:1471-5.
144. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003; 327:794-8.
145. Boguniewicz M, Fiedler VC, Raimer S et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102:637-44.
146. Lan CC, Huang CC, Chen YT et al. Tacrolimus ointment for the treatment of atopic dermatitis: report of first clinical experience in Taiwan. Kaohsiung J Med Sci 2003; 19:296-304.
147. Won CH, Seo PG, Park YM et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatolog Treat 2004; 15:30-4.
148. Freeman AK, Serle J, van Veldhuisen P et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004; 73:267-71.
149. Chapman MS, Schachner LA, Breneman D et al. Tacrolimus ontment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 2005; 53 (2 Suppl. 2):S177-85.
150. Koo JY, Fleischer AB Jr, Abramovits W et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53 (2 Suppl. 2):S195-205.
151. Reitamo S, Rustin M, Ruzicka T et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109:547-55.
152. Reitamo S, Harper J, Bos JD et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150:554-62.
153. Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003; 72:161-6.
154. Pacor ML, Di Lorenzo G, Martinelli N et al. Tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy 2004; 34:639-45.
155. van Leent EJ, Graber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134:805-9.
156. Kaufmann R, Folster-Holst R, Hoger P et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004; 114:1183-8.
157. Luger T, van Leent EJ, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144:788-94.
158. Kapp A, Papp K, Bingham A et al. Reduction in Eczema with Elidel (Infants) Multicenter Investigator Study Group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110:277-84.
159. Papp KA, Werfel T, Folster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005; 52:240-6.
160. Paller AS, Lebwohl M, Fleischer AB et al. Tacrolimus Ointment Study Group. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52:810-22.
161. Viglioglia P, Jones ML, Peets EA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res 1990; 18:460-7.
162. Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24:603-7.
163. Hoybye S, Balk Moller S, De Cunha Bang F et al. Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17-butyrate. Curr Ther Res Clin Exp 1991; 50:67-72.
164. Yawalkar SJ, Schwerzmann L. Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis. J Am Acad Dermatol 1991; 25:1163-6.
165. Guzzo CA, Weiss JS, Mogavero HS et al. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol 1991; 25:1179-83.
166. Brunner N, Yawalkar S. A double-blind, multicenter, parallel-group trial with 0.05% halobetasol propionate ointment versus 0.1% diflucortolone valerate ointment in patients with severe, chronic atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol 1991; 25:1160-3.
167. Datz B, Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol 1991; 25:1157-60.
168. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol 1991; 25:1166-9.
169. Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J Dermatolog Treat 1992; 3 (Suppl. 2):13-15.
170. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992; 27:29-34.
171. Rajka G, Avrach W, Gartner L, Overgaard-Petersen H. Mometasone furoate 0.1% fatty cream once daily versus betamethasone valerate 0.1% cream twice daily in the treatment of patients with atopic and allergic contact dermatitis. Curr Ther Res Clin Exp 1993; 54:23-9.
172. Bleehen SS, Chu AC, Hamann I et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133:592-7.
173. Koopmans B, Lasthein AB, Mork NJ et al. Multicentre randomized double-blind study of Locoid Lipocream fatty cream twice daily versus Locoid Lipocream once daily and Locobase once daily. J Dermatolog Treat 1995; 6:103-6.
174. Jorizzo J, Levy M, Lucky A et al. Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 1995; 33:74-7.
175. Lawlor F. Prednicarbate 0.25% ointment in the treatment of atopic dermatitis: a vehicle-controlled double-blind study. J Dermatolog Treat 1995; 6:233-5.
176. Aliaga A, Rodriguez M, Armijo M et al. Double-blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis. Int J Dermatol 1996; 35:131-2.
177. Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther 1997; 19:710-19.
178. Traulsen J. Hydrocortisone buteprate versus betamethasone valerate for once-daily treatment of atopic dermatitis. J Dermatolog Treat 1997; 8:109-14.
179. Maloney JM, Morman MR, Stewart DM et al. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol 1998; 37:142-4.
180. Hanifin JM, Hebert AA, Mays SR et al. Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res Clin Exp 1998; 59:227-33.
181. Wolkerstorfer A, Strobos MA, Glazenburg EJ et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 1998; 39:226-31.
182. van der Meer JB, Glazenburg EJ, Mulder PGH et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999; 140:1114-21.
183. Faergemann J, Christensen O, Sjovall P et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000; 14:393-6.
184. Pei AYS, Chan HHL, Ho KM. The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol 2001; 18:343-8.
185. Cato A, Swinehart JM, Griffin EI et al. Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis. Int J Dermatol 2001; 40:232-6.
186. Chunharas A, Wisuthsarewong W, Wananukul S, Viravan S. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. J Med Assoc Thailand 2002; 85:482-7.
187. Tan M-H, Meador SL, Singer G, Lebwohl MG. An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas. Int J Dermatol 2002; 41:804-9.
188. Prado de Oliveira ZN, Cuce LC, Arnone CA. Comparative evaluation of efficacy, tolerability and safety of 0.1% topical momethasone furoate and 0.05% desonide in the treatment of childhood atopic dermatitis. An Bras Dermatol 2002; 77:25-33.
189. Thomas KS, Armstrong S, Avery A et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002; 324:768.
190. Kawashima M, Tango T, Noguchi T et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148:1212-21.
191. Kirkup ME, Birchall NM, Weinberg EG et al. Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream. J Dermatolog Treat 2003; 14:141-8.
192. Kantor I, Milbauer J, Posner M et al. Efficacy and safety of emollients as adjunctive agents in topical corticosteroid therapy for atopic dermatitis. Today's Ther Trends 1993; 11:157-66.
193. Gip L, Lindberg L, Nordin P et al. Clinical study of mometasone furoate cream 0.1% compared to hydrocortisone butyrate cream 0.1% in treatment of atopic and seborrheic dermatitis. Today's Ther Trends 1990; 8:21-34.
194. Carpenter CL, Jolly HW, McCormick GE et al. Combined steroid-antiinfective topical therapy in common dermatoses: a double-blind, multi-center study of iodochlorhydroxyquin-hydrocortisone in 277 patients. Curr Ther Res Clin Exp 1973; 15:650-9.
195. Laurberg G. Topical treatment with urea-hydrocortisone in atopic dermatitis. A controlled study against betamethasone 17-valerate. Dermatologica 1975; 151:30-3.
196. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95:323-8.
197. Fattah AA, el-Shiemy S, Faris R, Tadros SS. A comparative clinical evaluation of a new topical steroid 'halcinonide' and hydrocortisone in steroid-responsive dermatoses. J Int Med Res 1976; 4:228-31.
198. el-Hefnawi H, el-Shiemy S, Paris R, Tadros SS. Double-blind paired comparison clinical trial of halcinonide and hydrocortisone. Cutis 1978; 22:97-9.
199. Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4:126-31.
200. Abdel Aal H, Abdallah MA, Iskandar IO, Salama NR. Clinical experience with 0.05% halometasone/1% triclosan cream in the treatment of acute infected and infection-prone eczema in Egypt. J Int Med Res 1987; 15:383-90.
201. Korting HC, Zienicke H, Braun-Falco O et al. Modern topical glucocorticoids and anti-infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination? Infection 1994; 22:390-4.
202. Poyner TF, Dass BK. Comparative efficacy and tolerability of fusidic acid/hydrocortisone cream (Fucidin™ H cream) and miconazole/hydrocortisone cream (Daktacort™ cream) in infected eczema. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 1):S23-9.
203. Ramsay CA, Savoie JM, Gilbert M et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 1):S15-22.
204. Hagstromer L, Nyren M, Emtestam L. Do urea and sodium chloride together increase the efficacy of moisturisers for atopic dermatitis skin? A comparative, double-blind and randomised study. Skin Pharmacol Appl Skin Physiol 2001; 14:27-33.
205. Loden M, Andersson A-C, Lindberg M. The effect of two urea-containing creams on dry, eczematous skin in atopic patients: II. Adverse effects. J Dermatolog Treat 1999; 10:171-5.
206. Loden M, Andersson A-C, Anderson C et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol (Stockh) 2002; 82:45-7.
207. Jemec GBE, Osterlind D. Cancer in patients treated with coal tar: a long-term follow up study. J Eur Acad Dermatol Venereol 1994; 3:1153-6.
208. Drake LA, Cohen L, Gillies R et al. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol 1999; 41:209-14.
209. Berberian BJ, Breneman DL, Drake LA et al. The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int J Dermatol 1999; 38:145-8.
210. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119:189-98.
211. Breneman DL, Hanifin JM, Berge CA et al. The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis 2000; 66:296-300.
212. R) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003; 148:1010-17.
213. Harper J. Double-blind comparison of an antiseptic oil-based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. Round Table Ser - R Soc Med 1995; 37:42-7.
214. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair), in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005; 15:31-6.
215. Haider SA. Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment. BMJ 1977; i:1570-2.
216. Kjellman NI, Gustafsson IM. Topical sodium cromoglycate in atopic dermatitis. A disappointing but informative trial. Allergy 1986; 41:423-8.
217. Stainer R, Matthews S, Arshad SH et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. Br J Dermatol 2005; 152:334-41.
218. 12 - a new therapeutic approach in atopic dermatitis - evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. Br J Dermatol 2004; 150:977-83.
219. de Prost Y, Bodemer C, Teillac D. Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis. Acta Derm Venereol (Stockh) 1989; 144 (Suppl.):136-8.
220. Hanifin JM, Chan SC, Cheng JB et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107:51-6.
221. Griffiths CE, van Leent EG, Gilbert M, Traulsen J. Cipamfylline Study Group. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol 2002; 147:299-307.
222. Hiroi J, Sengoku T, Morita K et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol 1998; 76:175-83.
223. Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol 2004; 15:294-303.
224. Bensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol 2005; 16:52-60.
225. Smitt JHS, Winterberg DH, Oosting J. Treatment of atopic dermatitis with topical corticosteroids in children. Efficacy and systemic effects of triamcinolone acetonide and alclometasone dipropionate. Eur J Dermatol 1993; 3:549-52.
226. Patel L, Clayton PE, Addison GM et al. Adrenal function following topical steroid treatment in children with atopic dermatitis. Br J Dermatol 1995; 132:950-5.
227. Wolkerstorfer A, Visser RL, de Waard-van der Spek FB et al. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol 2000; 143:999-1004.
228. Crespi HG. Topical corticosteroid therapy for children: alclometasone dipropionate cream 0.05% Clin Ther 1986; 8:203-10.
229. Lucky AW, Grote GD, Williams JL et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 1997; 59:151-3.
230. Hanifin JM. The role of topical steroids in the treatment of allergic skin disease. In: Towards Evolution of Allergic Skin Disease Management Hong Kong: Excerpta Medica, 1996; 1-2.
231. Moshang T. Prednicarbate emollient cream 0.1% in pediatric patients with atopic dermatitis. Cutis 2001; 68:63-9.
232. Paller AS, Nimmagadda S, Schachner L et al. Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. J Am Acad Dermatol 2003; 48:569-77.
233. Ruzicka T, Bieber T, Schopf E et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337:816-21.
234. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139:1184-6.